CellaVision AB (situated in Sweden) and Sysmex Europe GmbH (situated in Germany) have signed a Letter of Intent regarding distribution of CellaVision's products in selected countries, including Germany as an initial target.
Discussions regarding this and potential development collaboration within digital imaging and analysis in hematology will be conducted and concluded during the next couple of months.
"We are now about to enter the commercial phase of our unique technology developments", says Yvonne Mårtensson, CEO CellaVision AB. "Our first product, DiffMaster(TM), has passed the clinical test phase and is now ready for launch. Sysmex may turn out to be a perfect partner for us in our attempts to penetrate the market with the highest possible speed".